Assessment of osteoporosis in psoriasis with and without arthritis: Correlation with disease severity

International Journal of Dermatology

Volumn 50, Issue 1, 2011, Pages 30-35

  Attia, Enas A S ^a   Khafagy, Ayman ^a   Abdel Raheem, Sameh ^a   Fathi, Sahar ^a   Saad, Abeer A ^a  

^a AIN SHAMS UNIVERSITY   (Egypt)

Author keywords

[No Author keywords available]

Indexed keywords

OSTEOPROTEGERIN;

ADULT; ARTHROPATHY; ARTICLE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE DURATION; DISEASE SEVERITY; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; FEMUR; HUMAN; MALE; OSTEOPOROSIS; PSORIASIS; PSORIATIC ARTHRITIS; SCORING SYSTEM;

ABSORPTIOMETRY, PHOTON; ADULT; ARTHRITIS, PSORIATIC; FEMALE; FEMUR; HUMANS; MALE; MIDDLE AGED; NECK; OSTEOPOROSIS; OSTEOPROTEGERIN; PSORIASIS; SEVERITY OF ILLNESS INDEX; WRIST; YOUNG ADULT;

EID: 78650541117     PISSN: 00119059     EISSN: 13654632     Source Type: Journal    
DOI: 10.1111/j.1365-4632.2010.04600.x     Document Type: Article

References (29)

1. Brockbank J, Schentag CT, Rosen C, Gladman DD. Psoriatic arthritis (PsA) is common among patients with psoriasis and family medicine clinic attendees. Arthritis Rheum 2001; 44(Suppl): S94.
2. Harrison BJ, Hutchinson CE, Adams J, et al. Assessing periarticular bone mineral density in patients with early psoriatic arthritis or rheumatoid arthritis. Ann Rheum Dis 2002; 61: 1007-1011.
3. Walsh NC, Gravallese EM. Bone loss in inflammatory arthritis. Mechanisms and treatment strategies. Curr Opin Rheumatol 2004; 16: 419-427.
4. Li P, Schwarz EM, O'Keefe RJ, et al. Systemic TNF α promotes erosive bone resorption by increasing the number of CD11b+ osteoclast progenitors in the periphery which are dependent on RANK signaling for osteoclastogenesis. J Bone Miner Res 2002; 17S(Suppl): 130.
5. McGowan NW, Walker EJ, Macpherson H, et al. Cytokine-activated endothelium recruits osteoclast precursors. Endocrinology 2001; 142: 1678-1681.
6. Ritchlin CT, Haas-Smith SA, Li P, et al. Mechanisms of TNF-α-and RANKL-mediated osteoclastogenesis and bone resorption in psoriatic arthritis. J Clin Invest 2003; 111: 821-831.
7. Stolina M, Adamu S, Ominsky M, et al. RANKL is a marker and mediator of local and systemic bone loss in two rat models of inflammatory arthritis. J Bone Miner Res 2005; 20: 1756-1765.
8. Lam J, Takeshita S, Barker JE, et al. TNF-alpha induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand. J Clin Invest 2000; 106: 1481-1488.
9. Schett G, Stolina M, Bolon B, et al. Analysis of the kinetics of osteoclastogenesis in arthritic rats. Arthritis Rheum 2005; 52: 3192-3201.
10. Kastelan D, Kastelan M, Massari L, Korsic M. Possible association of psoriasis and reduced bone mineral density due to increased TNF-α and IL-6 concentrations. Med Hypotheses 2009; 67: 1403-1405.
11. Arican O, Aral M, Sasmaz S, Ciragil P. Serum levels of TNF-α, IFN-γ, IL-6, IL-8, IL-12, IL-17, and IL-18 in patients with active psoriasis and correlation with disease severity. Mediators Inflamm 2005; 5: 273-279.
12. Hofbauer LC, Shoppet M, Christ M, et al. Tumor necrosis factor α-related apoptosis-inducing ligand and osteoprotegrin in serum levels in psoriatic arthritis. Rheumatol 2006; 45: 1218-1222.
13. Borman P, Babaoǧlu S, Gur G, et al. Bone mineral density and bone turnover in patients with psoriatic arthritis. Clin Rheumatol 2008; 27: 443-447.
14. Taylor WJ, Helliwell PS, Gladman DD. A validation of current classification criteria for the diagnosis of psoriatic arthritis preliminary results of the CASPAR study. Ann Rheum Dis 2005; 64(Suppl 3): 107.
15. Wikpedia: Psoriasis Area Severity Index Accessed in November, 2009.
16. McHugh NG, Balachrishnan C, Jones SM. Progression of peripheral joint disease in psoriatic arthritis: a 5-yr prospective study. Rheumatol 2003; 42: 778-783.
17. Millard TP, Anoniades L, Evans AV, et al. Bone mineral density of patients with chronic plaque psoriasis. Clin Exp Dermatol 2001; 24: 446-448.
18. Kanis JA, Melton LJ, Chrestiansen C. The diagnosis of osteoporosis. J Bone Miner Res 1994; 9: 1137-1141.
19. Arican O, Bilgic K, Koc K. The effect of thyroid hormones in psoriasis vulgaris. Indian J Dermatol Venereol Leprol 2004; 70: 353-356.
20. Prasad P, Bikku B, Kaviarasan PK, Senthilnathan A. A clinical study of psoriatic arthropathy. Indian J Dermatol Venereol Leprol 2007; 73: 166-170.
21. Jones SM, Armas JB, Cohen MG, et al. Psoriatic arthritis: outcome of disease subset and relationship of joint disease to nail and skin disease. Br J of Rheumatol 1994; 23: 834-839.
22. Szulc P, Hofbauer LC, Heufelder AE, et al. Osteoprotegrin serum levels in men: correlation with age, estrogen, and testosterone status. J Clin Endocrinol Metab 2001; 86: 3162-3165.
23. Rogers A, Saleh G, Hannon RA, et al. Circulating estradiol and osteoprotegrin as determinants of bone turnover and bone density in postmenopausal women. J Clin Endocrinol Metab 2002; 87: 4470-4475.
24. Fahrleitner-Pammer A, Dobnig H, Piswanger-Soelkner C, et al. Osteoprotegrin serum levels in women: correlation with age, bone mass, bone turnover and fracture status. Wien Klin Wochenschr 2003; 115: 291-297.
25. Indridason OS, Franzson L, Sigurdsson G. Serum osteoprotegrin and its relationship with bone mineral density and markers of bone turnover. Osteoporos Int 2005; 16: 417-423.
26. Grisar J, Bernecker PM, Aringer M. Ankylosing spondylitis, psoriatic arthritis and reactive arthritis show increased bone resorption, but differ with regard to bone formation. J Rheumatol 2002; 29: 1430-1436.
27. Rogers A, Easstell R. Circulating osteoprotegrin and receptor activator for nuclear factor kappa B ligand: clinical utility in metabolic bone disease assessment. J Clin Endocrinol Metab 2005; 90: 6323-6331.
28. Khosla S, Arrighi HM, Melton LJ III, et al. Correlates of osteoprotegrin levels in women and men. Osteoporos Int 2002; 13: 394-399.
29. Kudlacek S, Schneider B, Woloszczuk W, et al. Serum levels of osteoprotegrin increase with age in a healthy adult population. Bone 2003; 32: 681-686.